NEW YORK – Cell imaging and analysis firm BioView said Wednesday that it has entered a collaboration with CTC capture firm Capio Biosciences to explore the integration of their respective technologies for development of a sample-to-answer clinical liquid biopsy assay.
Capio Biosciences' microfluidic CapioCyte technology employs a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture to improve the sensitivity and specificity of CTC isolations. BioView's DeNovo imaging and analysis system automates the detection and characterization of rare cells via rapid 3D imaging and AI-based deep learning analysis algorithms.
The companies have agreed to launch a joint study to evaluate the performance of an integrated solution combining their platforms for detection and characterization of prostate cancer CTCs stained for specific biomarkers.
The study will be led by Capio's president and cofounder, Seungpyo Hong, under a fee-for-service agreement with the University of Wisconsin. Other terms of the agreement were not disclosed.
According to BioView CEO Alan Schwebel, the goal of the collaboration is to create a user-friendly, standardized system that can help accelerate clinical translation.
"In order for CTCs to have true clinical utility, focused efforts should be made to introduce an automated, high-throughput, integrated, holistic back- and front-end solution that is standardized, easy to operate and offers significant clinical utility for both the patient and health provider," Schwebel said in a statement.